Core Points - The company announced a cash dividend distribution of 0.14 yuan per share for the third quarter of 2025, totaling approximately 106.24 million yuan [2][4] - The dividend distribution plan was approved at the annual shareholders' meeting on June 30, 2025, and does not require further shareholder approval [2][3] - The distribution will be made to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the registration date [3][4] Distribution Details - The total number of shares for the dividend calculation is 758,890,236 shares [4] - The cash dividend will be distributed through the clearing system of the China Securities Depository and Clearing Corporation, with specific instructions for shareholders who have or have not completed designated trading [5][6] - The company will not issue bonus shares or increase capital through this distribution [6] Taxation Information - For individual shareholders holding unrestricted shares, the cash dividend will not be subject to withholding tax at the time of distribution, with tax liabilities calculated based on holding periods upon stock transfer [9] - Different tax rates apply based on the holding period: 20% for holdings of one month or less, 10% for holdings between one month and one year, and no tax for holdings over one year [9] - For restricted shares, tax will be withheld at a rate of 10% for dividends received after the lifting of restrictions, resulting in a net dividend of 0.126 yuan per share [10] - For foreign institutional investors, a 10% withholding tax will also apply, resulting in a net dividend of 0.126 yuan per share [11]

Core Viewpoint - The company announced a cash dividend distribution plan for the third quarter of 2025, indicating a commitment to returning value to shareholders through direct cash payments [1] Group 1: Dividend Distribution - The total number of shares before the implementation of the plan is 758,890,236 [1] - A cash dividend of 0.14 yuan per share will be distributed, totaling 106,244,633.04 yuan (including tax) [1] - The cash dividends for major shareholders, including Lao Baixing Pharmaceutical Group Co., Ltd., Zexing Investment Co., Ltd., and Chen Xiulan, will be directly issued by the company [1]

Group 1 - The company announced a cash dividend distribution of 0.14 yuan per share (including tax), totaling 106 million yuan (including tax) based on a total share capital of 759 million shares prior to the distribution [1] - The record date for the dividend distribution is set for November 11, 2025, and the ex-dividend date is November 12, 2025 [1]

Core Points - The company announced a cash dividend distribution plan for the third quarter of 2025, with a total of 758,890,236 shares as the basis for the distribution [1] - Each share will receive a cash dividend of 0.14 yuan (including tax), amounting to a total cash dividend payout of 106,244,633.04 yuan (including tax) [1] - The cash dividends will be directly distributed to shareholders, including 老百姓医药集团有限公司, 泽星投资有限公司, and 陈秀兰 [1]

证券代码：603883 证券简称：老百姓 公告编号：2025-063 老百姓大药房连锁股份有限公司 2025年第三季度权益分派实施公告 重要内容提示： 每股分配比例 A 股每股现金红利0.14元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/11/11 | － | 2025/11/12 | 2025/11/12 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 30 日的2024年年度股东大会审议通过的《关于提请 股东大会授权董事会制定 2025 年中期分红方案的议案》授权公司董事会决定 2025 年中期（包 含半年度、前三季度）利润分配方案并实施，故本次利润分配方案无需提交股东大会审议。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ...

Core Viewpoint - The company announced a cash dividend distribution plan for the first half of 2025, with a total cash dividend of 106 million yuan to be distributed to shareholders [1] Group 1: Dividend Distribution Details - The total share capital before the distribution is 759 million shares [1] - The cash dividend per share is set at 0.14 yuan (including tax) [1] - The record date for the dividend distribution is November 11, 2025, and the ex-dividend date is November 12, 2025 [1]

Group 1 - The core argument is that the government aims to stimulate consumer spending to drive economic growth, as low consumer spending leads to a vicious cycle of reduced income and further decreased spending [1][10] - The current economic situation shows that many households are financially constrained, with 5.6 billion people having empty bank accounts and 90% of families having savings of less than 100,000 yuan [3][5] - The government is not merely pushing for increased spending but is trying to create an environment where consumers feel confident to spend by addressing their financial concerns [7][10] Group 2 - The government is implementing measures such as lowering deposit interest rates to encourage spending by making money feel less valuable, thus prompting consumers to spend rather than save [5][8] - Issuing consumption vouchers is intended to provide consumers with a sense of financial security, making them feel that their purchases are worthwhile [5][10] - The government recognizes that simply providing financial incentives is insufficient; it is focusing on improving income, social security, and reducing living costs to enhance consumers' spending capacity [10][11] Group 3 - The ultimate goal is to increase consumption growth rates to 5-6% and raise the proportion of final consumption in GDP to over 60%, which requires a multifaceted approach beyond just issuing consumption vouchers [10] - The shift in government strategy emphasizes enhancing consumer capability rather than just stimulating short-term spending, aiming for a healthier and more sustainable economy [10][11] - The government seeks to create a consumer environment where individuals feel they have the financial means and confidence to spend, thus revitalizing the consumption market [11]

Market Overview - The pharmaceutical commercial sector declined by 0.5% on November 4, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 11.85, up 10.03% [1] - Renmin Tongtai (600829) at 9.71, up 8.01% [1] - Jianfa Zhixin (301584) at 35.42, up 5.20% [1] - Baiyang Pharmaceutical (301015) saw a significant decline, closing at 25.62, down 6.09% [2] - Other notable decliners included: - Yifeng Pharmacy (603939) at 23.76, down 3.22% [2] - Saili Medical (603716) at 24.78, down 3.17% [2] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 32.34 million yuan from institutional investors, while retail investors saw a net outflow of 41.10 million yuan [2] - The capital flow for key stocks showed: - Renmin Tongtai had a net inflow of 63.04 million yuan from institutional investors [3] - Yifeng Pharmacy experienced a net outflow of 32.44 million yuan from retail investors [3]

Core Viewpoint - The company "老百姓" (Lao Bai Xing) has experienced fluctuations in stock performance and financial metrics, indicating a mixed outlook for its business operations and market position [1][2]. Group 1: Stock Performance - On November 4, the stock price of 老百姓 increased by 2.03%, reaching 17.10 CNY per share, with a trading volume of 120 million CNY and a turnover rate of 0.94%, resulting in a total market capitalization of 12.977 billion CNY [1]. - Year-to-date, the stock price has risen by 4.97%, with a 3.01% increase over the last five trading days, a 3.70% increase over the last 20 days, but a decline of 9.52% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 16.07 billion CNY, reflecting a year-on-year decrease of 1.00%, while the net profit attributable to shareholders was 529 million CNY, down 16.11% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 2.069 billion CNY, with 991 million CNY distributed over the past three years [2]. Group 3: Shareholder and Institutional Holdings - As of October 31, the number of shareholders for 老百姓 reached 63,700, an increase of 1.94% from the previous period, while the average circulating shares per person decreased by 1.90% to 11,921 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.7558 million shares, a decrease of 7.3246 million shares from the previous period [2].

Core Viewpoint - The pharmaceutical commercial sector experienced a short-term surge, with notable stock performances from various companies, indicating a positive market sentiment in this industry [1] Group 1: Company Performance - Renmin Tongtai reached the daily limit increase in stock price [1] - He富中国 achieved a consecutive six-day stock price increase [1] - Other companies such as Shuyu Pingmin, Jianfa Zhixin, Luyan Yiyao, Laobaixing, and Huaren Health also saw stock price increases [1]